Back to search
FDAFDA · Food and drugs·Recall number Z-2963-2020

Lactate Dehydrognease P-L, (UV), Catalog Number LD3818 - Product Usage: device intended for the quantitative in vitro determination of Lactate Dehydrogenase (LD) activity in serum and plasma. This product is suitable for use on the RX series instruments which includes the RX daytona and RX imola.

Published September 23, 2020 · Recall initiated: August 11, 2020

Summary

FDA records medical device Class II recall Z-2963-2020, published September 23, 2020 and initiated August 11, 2020. Recalling firm: Randox Laboratories Ltd.; Status: Terminated; Reported quantity: 4; Lot: GTIN: 05055273204117; Lot Numbers: 511979. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

An update to the carryover avoidance technical bulletin to introduce additional steps for reagent carryover avoidance with the Lactate Dehydrogenase assay on RX Instruments. Additional pipette washes can be implemented as described in the technical bulletin. Interference to the Lactate Dehydrogenase (LOH) reagent would be observed as inconsistencies in Quality Control recovery, which may lead to a delay in running patient samples, or erroneous elevated test results.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Randox Laboratories Ltd.
Distributor
US Nationwide distribution including in the states of WV, and Puerto Rico.
Lot
GTIN: 05055273204117; Lot Numbers: 511979
Risk classification
Class II
Area (FDA)
device
Country
Ireland

Related recalls

Questions about this recall

Was Lactate Dehydrognease P-L, (UV), Catalog Number LD3818 - Product Usage: device intended for the quantitative in vitro determination of Lactate Dehydrogenase (LD) activity in serum and plasma. This product is suitable for use on the RX series instruments which includes the RX daytona and RX imola. recalled?

Yes. FDA published recall Z-2963-2020 on September 23, 2020. Reported hazard: An update to the carryover avoidance technical bulletin to introduce additional steps for reagent carryover avoidance with the Lactate Dehydrogenase assay on RX Instruments. Additional pipette washes can be implemented as described in the technical bulletin. Interference to the Lactate Dehydrogenase (LOH) reagent would be observed as inconsistencies in Quality Control recovery, which may lead to a delay in running patient samples, or erroneous elevated test results.

What should I do if I have this product?

Voluntary: Firm initiated · Letter